PROCAM

The PROCAM study


Page: Go to Previous Page 3 of 9 Go to Next Page

The PROCAM study was initiated in 1979 and involved over 20,000 participants aged 16 to 65 years from 52 companies and government offices in the Münster and northern Ruhr areas of Germany (7). The first recruitment phase, which started in 1979, ended in late 1985 with 19,689 participants. The second and third rounds of recruitment from 1986-1991 and 1992-1995 added an additional 3,918 and 7,301 participants. Overall, the PROCAM study had roughly 30,000 participants (8). Recruited volunteers had no history of myocardial infarction (MI) or stroke and no electrocardiogram (ECG) evidence of ischemic heart disease. Examination at baseline included a case history questionnaire, measurement of blood pressure and anthropometric data, a resting ECG, and determination of several laboratory parameters. Follow-up was performed by questionnaire every two years, and cardiovascular events and deaths were confirmed by examining hospital records and/or eyewitness reports. The initial examination was repeated after 6 to 7 years.

As a whole, the PROCAM study was designed to study people for cardiovascular risk factors, mortality, and cardiovascular events (including MI and stroke). Its goal was to determine the prevalence of CVD risk factors in a German population and evaluate the relationship between risk factors and subsequent incidence of MI or death from CVD or other causes (8). A key objective of the PROCAM study was therefore to improve the methods used to estimate CVD risk.


Reference
Previous Reference
Next Reference
7. Assmann G, Cullen P and Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105: 310-5.
8. Cullen P, Schulte H and Assmann G. Smoking, lipoproteins and coronary heart disease risk. Data from the Munster Heart Study (PROCAM). Eur Heart J 1998; 19: 1632-41.

Document Center


Role of the Dysregulated Endocannabinoid System in Determining Cardiometabolic Risk by Vincenzo Di Marzo, PhD

Role of the Dysregulated Endocannabinoid System in Determining Cardiometabolic Risk by Vincenzo Di Marzo, PhD

More

What is the role of low HDL cholesterol in the elevated CHD risk of metabolic syndrome patients? By Philip J. Barter, MBBS, FRACP, PhD

What is the role of low HDL cholesterol in the elevated CHD risk of metabolic syndrome patients? By Philip J. Barter, MBBS, FRACP, PhD

More

Waist circumference: Getting it right! By Robert Ross, PhD

Waist circumference: Getting it right! By Robert Ross, PhD

More

Hypertrophy and hyperplasia of abdominal adipose tissues in women. Int J Obes (Lond) 2008;32:283-91

Hypertrophy and hyperplasia of abdominal adipose tissues in women. Int J Obes (Lond) 2008;32:283-91

More

Schematic representation of how smoking might add to several mechanisms linking obesity to cardiovascular disease

Schematic representation of how smoking might add to several mechanisms linking obesity to cardiovascular disease

More